Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
Investigating design rules for effective therapeutic cancer nano-vaccines
FY 2021-22
Summary
Traditional therapeutic cancer vaccine approaches typically involve injecting cancer patients with antigens (molecules that can trigger an immune response) specific to their own tumors, along with immune-stimulating agents called adjuvants, to amplify the response. However, the clinical success of traditional cancer vaccines has been limited by 1) the complexity of identifying patient-specific antigens and 2) the inefficient delivery of these antigens to the antigen presenting cells (APCs) of the immune system. Alternatively, broad immune-stimulating adjuvants can be directly injected into tumors to trigger APCs in the tumor into killing tumor cells, an approach termed in-situ vaccination.
Unfortunately, adjuvants can be taken up by cells non-specifically causing dose-limiting toxicity and can induce inflammatory toxicity when administered systemically. Therefore, efficient delivery of adjuvants to APCs in the tumour is
imperative for successful vaccination. Nanostructures are a promising class of carriers for delivering adjuvants to APCs because 1) APCs preferentially take up nanoscale materials, and 2) the surface of the nanostructures can be outfitted with high affinity ligands for APC cell-surface receptors. However, how the specific nanoscale design features, such as nanostructure shape and ligand spatial arrangement, can combine to promote nanostructure uptake by APCs remains unclear. A major limitation has been the inability to precisely control these design parameters in existing nanomaterials.
Using emerging advances in the field of DNA nanotechnology, I will investigate how nanostructure design can optimize adjuvant delivery to APCs ultimately leading to tumour eradication. The results of this research will provide a much needed outlook on how nanotechnology design can be leveraged in an in-situ cancer vaccine approach to provide a tangible clinical impact for cancer patients.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
458266
Name
Rothenbroker Meghan A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Investigating design rules for effective therapeutic cancer nano-vaccines
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Adjuvant Delivery; Cancer Nano-Vaccine; Cellular Uptake; Dna Nanotechnology; Dna Origami; In-Situ Vaccination; Structure-Function Relationship; T-Cell Activation
Abstract
Traditional therapeutic cancer vaccine approaches typically involve injecting cancer patients with antigens (molecules that can trigger an immune response) specific to their own tumors, along with immune-stimulating agents called adjuvants, to amplify the response. However, the clinical success of traditional cancer vaccines has been limited by 1) the complexity of identifying patient-specific antigens and 2) the inefficient delivery of these antigens to the antigen presenting cells (APCs) of the immune system. Alternatively, broad immune-stimulating adjuvants can be directly injected into tumors to trigger APCs in the tumor into killing tumor cells, an approach termed in-situ vaccination.
Unfortunately, adjuvants can be taken up by cells non-specifically causing dose-limiting toxicity and can induce inflammatory toxicity when administered systemically. Therefore, efficient delivery of adjuvants to APCs in the tumour is
imperative for successful vaccination. Nanostructures are a promising class of carriers for delivering adjuvants to APCs because 1) APCs preferentially take up nanoscale materials, and 2) the surface of the nanostructures can be outfitted with high affinity ligands for APC cell-surface receptors. However, how the specific nanoscale design features, such as nanostructure shape and ligand spatial arrangement, can combine to promote nanostructure uptake by APCs remains unclear. A major limitation has been the inability to precisely control these design parameters in existing nanomaterials.
Using emerging advances in the field of DNA nanotechnology, I will investigate how nanostructure design can optimize adjuvant delivery to APCs ultimately leading to tumour eradication. The results of this research will provide a much needed outlook on how nanotechnology design can be leveraged in an in-situ cancer vaccine approach to provide a tangible clinical impact for cancer patients.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Rothenbroker, Meghan A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~